Using pharmacologically-established medicines to treat COVID-19
A new suggestion has highlighted that the available pharmacologically-established existing medicines should be used to combat COVID-19.
List view / Grid view
Articles
Expert view: Critical consumables: meeting the need for a steady supply of microplates
In a time when rapid screening and fast-paced drug development are necessary for fighting illness and disease, having a robust supply of high-quality, fit-for-purpose consumables is critical.
Stem Cells In-Depth Focus 2020
The stem cells in-depth focus includes articles on using computational approaches to expand the applications of stem cell therapies and how organoids could be used to speed up the drug discovery process with a focus on retinal disease.
Imaging In-Depth Focus 2020
The articles in this in-depth focus discuss the difficulties in deciding what information to capture when imaging three-dimensional (3D) cell models and the use of non-invasive imaging techniques to discover small molecule drugs to control protein translation.
Immuno-oncology In-Depth Focus 2020
This in-depth focus features articles on using combinations of immuno-oncology drugs to target solid tumours and haematological cancers and how neoantigens of cancer cells could be used as the basis of novel immuno-oncology vaccines.
Screening In-Depth Focus 2020
Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).
Drug Target Review – Issue 2 2020
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
Empty phage viruses as a method to combat influenza
A group of German researchers has proposed an empty phage capsid with ligands on its surface as a novel technique to treat influenza.
Chemical formulas relevant to COVID-19 drug targets
Find several chemical formulas for potential COVID-19 therapeutics and drug targets currently in development here.
Can a computer help us find a treatment for COVID-19?
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
Utilising an interleukin-12 plasmid: a novel COVID-19 vaccine
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
Begin with the end in mind: designing synthetic antibiotics with a universal mechanism of action
James Graham from Recce Pharmaceuticals discusses how a new class of synthetic antibiotics could be the key to preventing the spread of antibiotic resistance.
Intravenous immunoglobulins, hyperimmunes and pandemic viruses
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
Developing respiratory therapeutics for prophylaxis and treatment
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
Cytokine storms: a major killer in patients with severe COVID-19 infection
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
